Latest News & Features
Americas
Biotech company submitted a petition challenging an ‘incorrect’ ruling by the Court of Appeals for the Federal Circuit | Earlier decision invalidated several of Vanda’s patents in its sleep drug dispute against a pair of big pharma firms. 16 January 2024
Big Pharma
US biotech has launched multiple suits over alleged infringement of Eylea patents | Regeneron asks US court to block Amgen’s biosimilar before potential approval. 16 January 2024
Big Pharma
Case concerns a supplementary protection certificate granted to Gilead by Finland’s Patent Office for a HIV drug |CJEU judges contradict AG opinion on whether a Finnish regime is at odds with an EU directive. 11 January 2024
Biotechnology
SCOTUS ignored Fed Circ cases and so-called Wands factors in reaching enablement decision | Pivotal question left unanswered | New guidance ‘provides clarity’ and reinforces status quo on enablement decisions. 11 January 2024
Generics
Judge says Bayer racked up high costs ‘in pursuit of vague point of principle’ | Teva and others wanted presentation slides as part of patent invalidity suit. 9 January 2024
Big Pharma
Generics companies have often inveighed against the “arbitrary and capricious” rule | Judicial immunity granted to Vidal’s decisions at odds with Congress and SCOTUS precedent, say generics and big tech. 9 January 2024
Big Pharma
Dispute hinges on clauses set out in decade-old settlement and licensing agreement | Federal Circuit unpersuaded by arguments suggesting that a federal court erred in denying a preliminary injunction. 4 January 2024
Americas
California-based drugmaker lost Hatch-Waxman Act case after judge ruled it had failed to show patent infringement | Corcept CEO ‘confident’ decision will be reversed on appeal. 4 January 2024
Big Pharma
District judge ruled in favour of Regeneron confirming patent infringement by Mylan | Court recognised Mylan's success in challenging the validity of certain patents | Ruling happened while Regeneron filed a separate case against another competitor alleging the infringement of 51 patents. 2 January 2024
Big Pharma
Life science attorneys should see some notable developments relating to artificial intelligence, patent eligibility and the Fintiv rule, write Manita Rawat and Alexander Stein of Morgan Lewis. 2 January 2024